UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2148-8
Program Prior Authorization/Medical Necessity
Medication Haegarda® (C1 esterase inhibitor, human)
P&T Approval Date 7/2018, 7/2019, 6/2020, 3/2021, 3/2022, 3/2023, 3/2024, 3/2025
Effective Date 6/1/2025
1. Background:
Haegarda is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH)
indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in patients 6
years of age and older.1
2. Coverage Criteria a:
A. Initial Authorization
1. Haegarda will be approved based on all of the following criteria:
a. Diagnosis of hereditary angioedema (HAE) as confirmed by one of the following:
(1) C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as
documented by one of the following (per laboratory standard):
(a) C1-INH antigenic level below the lower limit of normal
(b) C1-INH functional level below the lower limit of normal
-OR-
(2) HAE with normal C1 inhibitor levels and one of the following:
(a) Confirmed presence of variant(s) in the gene(s) for factor XII, angiopoietin-
1, plasminogen-1, kininogen-1, myoferlin, and heparan sulfate-glucosamine
3-O-sulfotransferase 6
(b) Recurring angioedema attacks that are refractory to high-dose
antihistamines with confirmed family history of angioedema
(c) Recurring angioedema attacks that are refractory to high-dose
antihistamines with unknown background de-novo mutation(s) (i.e., no
family history) (HAE-unknown)
-AND-
b. All of the following:
(1) Prescribed for the prophylaxis of HAE attacks
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
(2) Not used in combination with other products indicated for prophylaxis against
HAE attacks (e.g., Cinryze, Orladeyo, Takhzyro)
-AND-
(3) Prescriber attests that patient has experienced attacks of a severity and/or
frequency such that they would clinically benefit from prophylactic therapy
with Haegarda
-AND-
c. Prescribed by one of the following:
(1) Immunologist
(2) Allergist
Authorization of therapy will be issued for 12 months.
B. Reauthorization
1. Haegarda will be approved based on all of the following criteria:
a. Documentation of positive clinical response to Haegarda therapy
-AND-
b. Reduction in the utilization of on-demand therapies used for acute attacks (e.g.,
Berinert, Firazyr, Ruconest) as determined by claims information, while on
Haegarda therapy
-AND-
c. Both of the following:
(1) Prescribed for the prophylaxis of HAE attacks
-AND-
(2) Not used in combination with other products indicated for prophylaxis against
HAE attacks (e.g., Cinryze, Orladeyo, Takhzyro)
-AND-
d. Prescribed by one of the following:
(1) Immunologist
(2) Allergist
Authorization of therapy will be issued for 12 months.
© 2025 UnitedHealthcare Services, Inc.
2
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Haegarda [package insert]. Kankakee, IL: CSL Behring, LLC; January 2022.
2. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the
management of hereditary angioedema-The 2017 revision and update. Allergy. 2018 Jan 10.
3. Wu, E. Hereditary angioedema with normal C1 inhibitor. In: UpToDate, Saini, S (Ed),
UpToDate, Waltham, MA, 2023.
4. Busse, P., Christiansen, S., Riedl, M., et. al. “US HAEA Medical Advisory Board 2020
Guidelines for the Management of Hereditary Angioedema.” The Journal of Allergy and
Clinical Immunology. 2020 September 05.
5. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the
management of hereditary angioedema-The 2021 revision and update. Allergy.
2022;77(7):1961-1990. doi:10.1111/all.15214
Program Prior Authorization/Medical Necessity - Haegarda (C1 esterase inhibitor,
human)
Change Control
7/2018 New program.
7/2019 Annual review. No changes made to program.
6/2020 Annual review. Aligned criteria with acute and prophylactic therapies.
3/2021 Added diagnosis criteria and aligned combination use language with
prophylactic therapies. Updated references.
3/2022 Annual review. Updated background and references.
3/2023 Annual review. Updated combination use language with prophylactic
therapies without change to clinical intent. Updated references.
3/2024 Annual review with update to diagnostic criteria for HAE with normal C1
inhibitor levels. Updated language for reauthorization criteria.
3/2025 Annual review. No changes to the clinical criteria.
© 2025 UnitedHealthcare Services, Inc.
3